KR100412219B1 - 분자 요오드의 경구투여용 제약 조성물 - Google Patents

분자 요오드의 경구투여용 제약 조성물 Download PDF

Info

Publication number
KR100412219B1
KR100412219B1 KR10-2000-7003542A KR20007003542A KR100412219B1 KR 100412219 B1 KR100412219 B1 KR 100412219B1 KR 20007003542 A KR20007003542 A KR 20007003542A KR 100412219 B1 KR100412219 B1 KR 100412219B1
Authority
KR
South Korea
Prior art keywords
iodide
iodine
delete delete
molecular
molecular iodine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR10-2000-7003542A
Other languages
English (en)
Korean (ko)
Other versions
KR20010030861A (ko
Inventor
용준 두안
존 힉키
릭 파나쿠치
잭 케슬러
Original Assignee
심볼론 코포레이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 심볼론 코포레이션 filed Critical 심볼론 코포레이션
Publication of KR20010030861A publication Critical patent/KR20010030861A/ko
Application granted granted Critical
Publication of KR100412219B1 publication Critical patent/KR100412219B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/18—Iodine; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/40—Peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
KR10-2000-7003542A 1997-10-29 1998-10-27 분자 요오드의 경구투여용 제약 조성물 Expired - Fee Related KR100412219B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US960149 1997-10-29
US08/960,149 US5885592A (en) 1997-10-29 1997-10-29 Methods and pharmaceutical compositions for oral delivery of molecular iodine

Publications (2)

Publication Number Publication Date
KR20010030861A KR20010030861A (ko) 2001-04-16
KR100412219B1 true KR100412219B1 (ko) 2003-12-24

Family

ID=25502851

Family Applications (1)

Application Number Title Priority Date Filing Date
KR10-2000-7003542A Expired - Fee Related KR100412219B1 (ko) 1997-10-29 1998-10-27 분자 요오드의 경구투여용 제약 조성물

Country Status (17)

Country Link
US (1) US5885592A (cg-RX-API-DMAC7.html)
EP (1) EP1024815B1 (cg-RX-API-DMAC7.html)
JP (1) JP4187410B2 (cg-RX-API-DMAC7.html)
KR (1) KR100412219B1 (cg-RX-API-DMAC7.html)
CN (1) CN1150904C (cg-RX-API-DMAC7.html)
AT (1) ATE231725T1 (cg-RX-API-DMAC7.html)
AU (1) AU750627B2 (cg-RX-API-DMAC7.html)
BR (1) BR9812588A (cg-RX-API-DMAC7.html)
CA (1) CA2301503C (cg-RX-API-DMAC7.html)
DE (1) DE69811105T2 (cg-RX-API-DMAC7.html)
DK (1) DK1024815T3 (cg-RX-API-DMAC7.html)
ES (1) ES2191973T3 (cg-RX-API-DMAC7.html)
IL (1) IL134778A0 (cg-RX-API-DMAC7.html)
NO (1) NO20001673L (cg-RX-API-DMAC7.html)
PT (1) PT1024815E (cg-RX-API-DMAC7.html)
RU (1) RU2213564C2 (cg-RX-API-DMAC7.html)
WO (1) WO1999021567A1 (cg-RX-API-DMAC7.html)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6248335B1 (en) * 1997-10-29 2001-06-19 Symbollon Corporation Stabilized oral pharmaceutical composition containing iodide and iodate and method
CA2317587A1 (en) * 1998-01-06 1999-07-15 Fujisawa Pharmaceutical Co., Ltd. Solid iodophor preparations and process for producing the same
JP2002518351A (ja) * 1998-06-19 2002-06-25 オキシバイオ・インコーポレイテッド 抗感染および避妊特性を有する医療装置
US6154672A (en) * 1998-06-22 2000-11-28 Pacesetter, Inc. Method and apparatus for improving the probability of success of defibrillation shocks
GB2395901A (en) * 1999-02-26 2004-06-09 Symbollon Corp Stabilised tablets containing iodide and iodate
PT1195178E (pt) * 2000-10-06 2006-10-31 Dmg Italia Srl Preparacao imunotrofica para o tratamento da hipertrofia adenoamigdalar.
RU2201229C1 (ru) * 2002-03-26 2003-03-27 Миронов Владимир Андреевич Способ оздоровления организма
ATE497351T1 (de) * 2003-06-20 2011-02-15 Hills Pet Nutrition Inc Verfahren für die schilddrüsenüberfunktion bei der katze sowie zusammensetzungen mit eingeschränktem jodgehalt
US8501223B2 (en) * 2003-06-20 2013-08-06 Hill's Pet Nutrition, Inc. Methods for dietary management of cats to avoid hyperthyroidism
JP5356831B2 (ja) * 2006-01-26 2013-12-04 ヒルズ・ペット・ニュートリシャン・インコーポレーテッド ネコ科動物の甲状腺機能亢進症を治療するための方法及び組成物
CN101489411A (zh) * 2006-05-12 2009-07-22 希尔氏宠物营养品公司 用于预防或治疗具有甲状腺机能亢进的猫科动物的慢性肾衰竭的组合物和方法
US8303994B2 (en) * 2006-06-22 2012-11-06 Jack Howard Kessler Method for the eradication of pathogens including S. aureus and antibiotic resistant microbes from the upper respiratory tract of mammals and for inhibiting the activation of immune cells
CA2656608C (en) * 2006-07-03 2014-09-16 Hill's Pet Nutrition, Inc. Compositions and methods for preventing or treating cardiovascular diseases in felines with hyperthyroidism
US20080063560A1 (en) * 2006-09-07 2008-03-13 Biolargo Life Technologies, Incorporated Ground treatment for reducing microbial content
US7943158B2 (en) * 2006-09-07 2011-05-17 BioLargo Life Technologies, Inc Absorbent systems providing antimicrobial activity
US8226964B2 (en) * 2006-09-07 2012-07-24 Biolargo Life Technologies, Inc. Systems and methods for cleaning liquid carriers related applications data
US9414601B2 (en) * 2006-09-07 2016-08-16 Biolargo Life Technologies, Incorporated Material having antimicrobial activity when wet
US7867510B2 (en) * 2006-09-07 2011-01-11 BioLargo Life Technologies, Inc Material having antimicrobial activity when wet
US8021610B2 (en) * 2006-09-07 2011-09-20 Biolargo Life Technologies, Inc. Systems providing antimicrobial activity to an environment
US8257749B2 (en) * 2007-02-08 2012-09-04 Biolargo Life Technologies, Incorporated Systems providing at least pesticidal activity
WO2009087647A1 (en) * 2008-01-07 2009-07-16 Council Of Scientific & Industrial Research A stabilized iodine-water concentrate formulation useful for protection against iodine deficiency disorders
MX340005B (es) * 2010-04-23 2016-05-18 Univ Nac Autónoma De México Composicion de yodo molecular de uso humano para la prevencion y tratamiento de patologias prostaticas.
US20140072598A1 (en) * 2011-05-16 2014-03-13 Shokan Sabirkhanovich Begaliev Medicinal preparation "renessans" having an antibacterial, anti-ulcerous and immuno-modulating action
CN102697804B (zh) * 2012-06-07 2014-02-12 维尔信科技(潍坊)有限公司 一种固态分子碘消毒制剂及其制备方法
US10034899B2 (en) * 2013-11-27 2018-07-31 BioPharmX, Inc. Solid oral dosage form for breast symptoms
WO2015120458A1 (en) * 2014-02-10 2015-08-13 Fred Hutchinson Cancer Research Center Halogen treatment of heart attack and ischemic injury
SG11201607686VA (en) 2014-03-31 2016-10-28 Iotech International Inc Stable compositions of uncomplexed iodine and methods of use
EA031907B1 (ru) * 2016-03-11 2019-03-29 Тимур Хусаинович Измайлов Шашка иодная дымовая
WO2017185060A1 (en) 2016-04-21 2017-10-26 BioPharmX, Inc. Oral iodine dosage form
CA3031447A1 (en) 2016-07-21 2018-01-25 Iogen, Llc Emollient topical disinfectants
CN106727683A (zh) * 2016-12-23 2017-05-31 刘海涛 一种药物制剂在制备治疗幽门螺杆菌感染性疾病的药物中的应用
WO2021198938A1 (ja) * 2020-03-31 2021-10-07 タイ ミン ファーマシューティカルズ ジェイエスシー 癌または子宮内膜症の患者における癌、子宮内膜症および疼痛の治療のためのジイソプロピルアミン化合物およびヨウ素
BR112023001995A2 (pt) 2020-08-13 2023-02-28 I2Pure Corp Composições de alta concentração de iodo molecular, formulações farmacêuticas, preparação e usos
US20240350534A1 (en) * 2020-12-12 2024-10-24 Iocure, Inc. Iodine delivery compounds
WO2024201560A1 (en) * 2023-03-24 2024-10-03 Me.Link Co., Ltd. Iodine containing colloidal liquid composition

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2540170C3 (de) * 1975-09-10 1979-01-18 Basf Ag, 6700 Ludwigshafen Verwendung von in organischer Lösung hergestelltem Polyvinylpyrrolidon zur Herstellung von stabilen wäßrigen PoIyvinylpyrrolidon-Jod-Lösungen
US4259322A (en) * 1978-03-20 1981-03-31 Helong Lim Method of treatment of tuberculosis
US4187294A (en) * 1978-07-06 1980-02-05 Nihon Nousan Kougyou Co., Ltd. Method for producing eggs containing a high amount of iodinated amino acids
JPS5663919A (en) * 1979-10-29 1981-05-30 Nippon Nousan Kogyo Kk Remedial composition for diabetes
JPS57140723A (en) * 1981-02-25 1982-08-31 Nippon Nousan Kogyo Kk Preventing composition for hyperlipemia due to neutral fat
US5589198A (en) * 1985-07-31 1996-12-31 943038 Ontario, Inc. Treatment of iodine deficiency diseases
US5250304A (en) * 1985-07-31 1993-10-05 Ghent William R Treatment of iodine deficiency diseases
US4816255A (en) * 1985-07-31 1989-03-28 Ghent William R Treatment of iodine deficiency breast syndrome
US5171582A (en) * 1985-07-31 1992-12-15 Ghent William R Treatment of iodine deficiency diseases
US4849237A (en) * 1987-10-30 1989-07-18 Hurst William D Method for sanitizing poultry carcasses in a poultry processing plant utilizing ozonated water
US5629024A (en) * 1994-08-22 1997-05-13 Symbollon Corporation Method of forming an iodine based germicide composition

Also Published As

Publication number Publication date
JP2003510243A (ja) 2003-03-18
NO20001673L (no) 2000-05-24
JP4187410B2 (ja) 2008-11-26
EP1024815B1 (en) 2003-01-29
KR20010030861A (ko) 2001-04-16
CA2301503A1 (en) 1999-05-06
CN1150904C (zh) 2004-05-26
AU1122799A (en) 1999-05-17
DK1024815T3 (da) 2003-05-19
PT1024815E (pt) 2003-06-30
US5885592A (en) 1999-03-23
BR9812588A (pt) 2000-07-25
IL134778A0 (en) 2001-04-30
DE69811105T2 (de) 2003-11-06
ATE231725T1 (de) 2003-02-15
ES2191973T3 (es) 2003-09-16
NO20001673D0 (no) 2000-03-31
CA2301503C (en) 2005-01-04
RU2213564C2 (ru) 2003-10-10
DE69811105D1 (de) 2003-03-06
WO1999021567A1 (en) 1999-05-06
CN1272789A (zh) 2000-11-08
AU750627B2 (en) 2002-07-25
EP1024815A1 (en) 2000-08-09

Similar Documents

Publication Publication Date Title
KR20010030861A (ko) 분자 요오드의 경구투여용 제약 조성물
FI77371B (fi) Foerfarande foer framstaellning av en kapsel, som innehaoller ett alkaliskt aemne och acetylsalicylsyra.
DE3020724C2 (de) Verfahren zur Herstellung pharmazeutischer Zusammensetzungen mit Retardwirkung
AU778774B2 (en) Stabilized oral pharmaceutical composition containing iodide and iodate and method
JP2907299B2 (ja) 胃酸を結合する薬学的製剤
CN102550601A (zh) 一种碘伏消毒液及其制备方法
US20180296594A1 (en) Solid oral dosage form for breast symptoms
US20170172960A1 (en) Pharmaceutical formulations for treating kidney stones and methods for fabricating and using thereof
CS208475B2 (en) Method of making the hydrogencitrate of the alcalic met
JPH06508105A (ja) 乾燥デンプン−ヨウ素医薬処方剤
MXPA00003219A (en) Pharmaceutical compositions for oral administration of molecular iodine
Melikian et al. Bioavailability of potassium from three dosage forms: suspension, capsule, and solution
Harrington et al. Effects of ClO2 on the absorption and distribution of dietary iodide in the rat
KR960015954B1 (ko) 위장질환 치료제
EP0444931B1 (en) Use of 3-oxygermylpropionic acid to treat and prevent diabetes due to autoimmune diseases
US20030026852A1 (en) Molecular iodine pharmaceutical composition
Stair et al. Lead arsenate poisoning in a herd of beef cattle
WO2003103689A1 (en) Molecular iodine pharmaceutical composition
Kumar A Comprehensive Textbook of Pharmaceutical Inorganic Chemistry: As Per New PCI Syllabus for B. Pharmacy, BP-104 T
Nelson Urinary Excretion Kinetics for Evaluation of Drug Absorption II: Constant, Rate-Limited Release of Tetracycline After Ingestion By Humans
HU227054B1 (hu) Késleltetett kioldódású, stabilizált jódsótabletta, eljárás ennek elõállítására, és alkalmazása radiojódszennyezõdés kiürítésére
JPS645008B2 (cg-RX-API-DMAC7.html)

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

FPAY Annual fee payment

Payment date: 20071204

Year of fee payment: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20081211

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20081211